linaclotide (Rx)

>10%

IBS-C

• Diarrhea (20%)

CIC

• Diarrhea (16-22%)

1-10%

IBS-C

• Abdominal pain (7%)
• Flatulence (4%)
• Headache (4%)
• Viral gastroenteritis (3%)
• Abdominal distension (2%)
• Severe diarrhea (2%)
• Defecation urgency (<2%)
• Fecal incontinence (<2%)
• Vomiting (<2%)
• Gastroesophageal reflux disease (<2%)

CIC

• Abdominal pain (7%)
• Flatulence (6%)
• Upper respiratory tract infection (5%)
• Sinusitis (3%)
• Abdominal distension (1-3%)
• Defecation urgency (<2%)
• Fecal incontinence (<2%)
• Dyspepsia (<2%)
• Viral gastroenteritis (<2%)

FC

• Diarrhea (4%)

Frequency Not Defined

FC

• Nausea
• Abdominal discomfort
• Dehydration

Postmarketing Reports

Hypersensitivity reactions: Anaphylaxis, angioedema, rash (including hives or urticaria)

Gastrointestinal reactions: Hematochezia, nausea, rectal hemorrhage

Contraindications

Patients aged <2 years due to risk of serious dehydration

Known or suspected mechanical gastrointestinal obstruction

Cautions

Pediatric risk

• Contraindicated in patients <2 years of age
• In neonatal mice, fluid secretion increased because of GC-C agonism resulting in mortality within the first 24 hr due to dehydration
• There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to <18 years of age; there are insufficient data available on GC-C intestinal expression in children aged <2 years to assess the risk of developing diarrhea and its potentially serious consequences in these patients

Diarrhea

• Diarrhea was the most common adverse reaction in clinical trials
• In postmarketing reports, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or IV fluid administration have been reported
• Diarrhea reported in pediatric patients 6-17 years with functional constipation receiving therapy
• If severe diarrhea occurs, suspend dosing and rehydrate

Pregnancy

Linaclotide and its active metabolite are negligibly absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure

Insufficient data available data on use in pregnant women to inform any drug-associated risk for major birth defects and miscarriage

Animal data

• No effects on embryofetal development were observed with oral administration of linaclotide in rats and rabbits during organogenesis at doses much higher than the maximum recommended human dosage
• Severe maternal toxicity associated with effects on fetal morphology were observed in mice

Lactation

Linaclotide and its active metabolite were not detected in the milk of lactating women; in adults, concentrations of linaclotide and its active metabolite were below the limit of quantitation in plasma following multiple doses of the drug

Maternal use of the drug is not expected to result in exposure to the drug or its active metabolite in breastfed infants; there is no information on effects on milk production; consider developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from the drug or from the underlying maternal condition

No lactation studies in animals have been conducted

Unknown whether negligible systemic absorption of linaclotide by adults will result in a clinically relevant exposure to breastfed infants

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Guanylate cyclase C (GC-C) agonist; activation of GC-C located on the luminal surface of intestinal epithelial cells leads to increased cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit

Appears to work topically rather than systemically; elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit

Absorption

Minimal systemic absorption

Concentrations of linaclotide and its active metabolite in plasma are below the limit of quantitation after oral doses of 145 mcg or 290 mcg

Metabolism

Metabolized within the GI tract to its principal, active metabolite by loss of the terminal tyrosine moiety

Both linaclotide and the metabolite are proteolytically degraded within the intestinal lumen to smaller peptides and naturally occurring amino acids

Elimination

Excretion: 3-5% feces (parent compound) and virtually 100% of active metabolite

Oral Administration

Take on an empty stomach at least 30 minutes before first meal of the day, at approximately the same time each day

Swallow capsule whole; do not chew or crush

Missed dose

• Skip missed dose and take next dose at regular time; do not take 2 doses at the same time

Difficulty swallowing tablets

• May sprinkle capsule contents on applesauce or in water; not tested in other soft foods or liquids

• Administration in applesauce

  • Place 1 teaspoonful of applesauce at room temperature into a clean container
  • Open capsule
  • Sprinkle entire contents (beads) on applesauce
  • Consume entire contents immediately; do not chew beads; do not store applesauce-beads mixture for later use

• Administration in water

  • Pour ~1 ounce (30 mL) of bottled water at room-temperature into clean cup
  • Open capsule
  • Sprinkle entire contents (beads) into water
  • Gently swirl beads and water for at least 20 sec
  • Swallow entire mixture of beads and water immediately
  • Add another 30 mL of water to any beads remaining in cup, swirl for 20 seconds, and swallow immediately
  • Do not store the bead-water mixture for later use
  • Note: Drug is coated on surface of the beads and will dissolve off the beads into water; beads will remain visible and will not dissolve; therefore, it is not necessary to consume all beads to deliver complete dose

• Nasogastric or gastric feeding tube administration in water

  • Open capsule and empty the beads into clean container with 1 ounce (30 mL) of room-temperature bottled water
  • Mix by gently swirling beads for at least 20 sec
  • Draw-up beads and water mixture to an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 sec) to dispense syringe contents into the tube
  • After administering the bead-water mixture, flush nasogastric/gastric tube with a minimum of 10 mL of water
  • Note: It is not necessary to flush all the beads through to deliver complete dose

Storage

Store at 25ºC (77ºF); excursions permitted between 15-30ºC (59-86ºF)

Keep in the original container; do not subdivide or repackage

Protect from moisture

Do not remove desiccant from the container

BRAND	FORM.	UNIT PRICE	PILL IMAGE
Linzess oral -	145 mcg capsule
Linzess oral -	72 mcg capsule
Linzess oral -	290 mcg capsule

Copyright © 2010 First DataBank, Inc.